UKI2S announces seed investment in Cagen
Summary
UKI2S and Imperial Innovations announced seed funding for Cagen, a synthetic biology spinout based at Imperial College London. Cagen develops self-assembling protein nanocages that can carry drugs more safely and improve their delivery to target sites. The company aims to help revive drug candidates that failed because of toxicity, solubility, or poor pharmacokinetics. Cagen is also working with a large pharmaceutical company to test how its nanocages can deliver complex payloads.
Funding
Amount
None
Total raised
Date
August 10, 2018
Announcement date
Investors
Imperial Innovations, Imperial College London, SynbiCITE, UK Innovation & Science Seed Fund
Lead investors
Company
-
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected